BAY1093884
Sponsors
Bayer
Conditions
HemophiliaHemophilia AHemophilia A; Hemophilia BHemophilia B
Phase 1
A Single Escalating Dose and Multiple Dose Study of BAY 1093884 in Subjects With Severe Hemophilia Types A or B, With or Without Inhibitors
CompletedNCT02571569
Start: 2015-10-28End: 2018-10-11Updated: 2018-10-18
A Study to Assess Pharmacokinetics and Pharmacodynamics Following Administration of BAY1093884 in Patients With Severe Hemophilia
CompletedNCT03481946
Start: 2018-05-10End: 2019-02-20Updated: 2020-09-16
Study to Test the Safety of an Investigational Drug Given Repeatedly to Adult Men With Severe Hemophilia
WithdrawnNCT03996486
Start: 2019-10-28End: 2020-07-31Updated: 2019-10-22